{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:09:34Z","timestamp":1789002574054,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T00:00:00Z","timestamp":1775347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["5\/3\/8\/72\/2020-ITR"],"award-info":[{"award-number":["5\/3\/8\/72\/2020-ITR"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-46619-2","type":"journal-article","created":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T09:23:51Z","timestamp":1775381031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["IL-11\u2013IL6ST\u2013STAT3 signaling defines a convergent inflammatory axis in esophageal cancer subtypes"],"prefix":"10.1038","volume":"16","author":[{"given":"Shayaq Ul Abeer","family":"Rasool","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad A.","family":"Pandith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farooq Ahmad","family":"Ganie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qurat ul","family":"Aein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usma","family":"Manzoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dil","family":"Afroze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aadil Manzoor","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zubaida","family":"Rasool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazir Ahmad","family":"Dar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Showkeen","family":"Muzamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,5]]},"reference":[{"issue":"10466","key":"46619_CR1","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/S0140-6736(24)02226-8","volume":"404","author":"H Yang","year":"2024","unstructured":"Yang, H. et al. Oesophageal cancer. Lancet 404 (10466), 1991\u20132005 (2024).","journal-title":"Lancet"},{"issue":"1","key":"46619_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40364-024-00718-2","volume":"13","author":"W Jin","year":"2025","unstructured":"Jin, W. et al. Global, regional, and national burden of esophageal cancer: a systematic analysis of the Global Burden of Disease Study 2021. Biomark. Res. 13 (1), 3 (2025).","journal-title":"Biomark. Res."},{"issue":"1","key":"46619_CR3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1186\/s12885-022-09657-3","volume":"22","author":"B Wang","year":"2022","unstructured":"Wang, B. et al. Cancer incidence and mortality and risk factors in member countries of the \u201cBelt and Road\u201d initiative. BMC Cancer 22(1), 582 (2022).","journal-title":"BMC Cancer"},{"issue":"5","key":"46619_CR4","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s13277-012-0418-z","volume":"33","author":"AA Pandith","year":"2012","unstructured":"Pandith, A. A. & Siddiqi, M. A. Burden of cancers in the valley of Kashmir: 5 year epidemiological study reveals a different scenario. Tumour Biol. 33 (5), 1629\u20131637 (2012).","journal-title":"Tumour Biol."},{"issue":"4","key":"46619_CR5","first-page":"e81794","volume":"17","author":"ML Munz","year":"2025","unstructured":"Munz, M. L. & Sampson, L. K. A case of coexistence of Esophageal Squamous Cell Carcinoma and Adenocarcinoma. Cureus 17(4), e81794 (2025).","journal-title":"Cureus"},{"issue":"3","key":"46619_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.asjsur.2016.10.005","volume":"41","author":"FL Huang","year":"2018","unstructured":"Huang, F. L. & Yu, S. J. Esophageal cancer: Risk factors, genetic association, and treatment. Asian J. Surg. 41 (3), 210\u2013215 (2018).","journal-title":"Asian J. Surg."},{"issue":"3","key":"46619_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5604\/01.3001.0054.4523","volume":"96","author":"B Strzelec","year":"2024","unstructured":"Strzelec, B., Chmielewski, P. P. & Kielan, W. Esophageal cancer: current status and new insights from inflammatory markers - a brief review. Pol. Przegl Chir. 96 (3), 83\u201387 (2024).","journal-title":"Pol. Przegl Chir."},{"key":"46619_CR8","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.22926.1","author":"K Harada","year":"2020","unstructured":"Harada, K. et al. Recent advances in treating oesophageal cancer.. F1000Res https:\/\/doi.org\/10.12688\/f1000research.22926.1 (2020).","journal-title":"F1000Res"},{"issue":"6","key":"46619_CR9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s11748-013-0246-0","volume":"61","author":"H Kato","year":"2013","unstructured":"Kato, H. & Nakajima, M. Treatments for esophageal cancer: A review. Gen. Thorac. Cardiovasc. Surg. 61(6), 330\u2013335 (2013).","journal-title":"Gen. Thorac. Cardiovasc. Surg."},{"issue":"7","key":"46619_CR10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1586\/17474124.2014.913478","volume":"8","author":"KE O\u2019Sullivan","year":"2014","unstructured":"O\u2019Sullivan, K. E. et al. The role of inflammation in cancer of the esophagus. Expert Rev. Gastroenterol. Hepatol. 8 (7), 749\u2013760 (2014).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"46619_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10555-022-10026-6","volume":"41","author":"T Sharma","year":"2022","unstructured":"Sharma, T. et al. Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis. Cancer Metastasis Rev. 41 (2), 281\u2013299 (2022).","journal-title":"Cancer Metastasis Rev."},{"issue":"1","key":"46619_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1615\/CritRevEukarGeneExpr.2013006033","volume":"23","author":"M Zhang","year":"2013","unstructured":"Zhang, M. et al. Role of cancer-related inflammation in esophageal cancer. Crit. Rev. Eukaryot. Gene Expr. 23(1), 27\u201335 (2013).","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"issue":"4","key":"46619_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2217\/imt.15.17","volume":"7","author":"TL Putoczki","year":"2015","unstructured":"Putoczki, T. L. & Ernst, M. IL-11 signaling as a therapeutic target for cancer. Immunotherapy 7 (4), 441\u2013453 (2015).","journal-title":"Immunotherapy"},{"issue":"1","key":"46619_CR14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4143\/crt.2018.031","volume":"51","author":"J Ma","year":"2019","unstructured":"Ma, J. et al. Cancer-associated fibroblasts promote the chemo-resistance in gastric cancer through secreting IL-11 targeting JAK\/STAT3\/Bcl2 pathway. Cancer Res. Treat. 51(1), 194\u2013210 (2019).","journal-title":"Cancer Res. Treat."},{"key":"46619_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030381","author":"L Sreenivasan","year":"2022","unstructured":"Sreenivasan, L. et al. Targeting the gp130\/STAT3 axis attenuates tumor microenvironment mediated chemoresistance in group 3 medulloblastoma cells. Cells https:\/\/doi.org\/10.3390\/cells11030381 (2022).","journal-title":"Cells"},{"key":"46619_CR16","doi-asserted-by":"publisher","first-page":"38408","DOI":"10.1038\/srep38408","volume":"6","author":"L Tao","year":"2016","unstructured":"Tao, L. et al. Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11\/IL-11R\/STAT3 signaling pathway. Sci. Rep. 6, 38408 (2016).","journal-title":"Sci. Rep."},{"issue":"2","key":"46619_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ccr.2013.06.017","volume":"24","author":"TL Putoczki","year":"2013","unstructured":"Putoczki, T. L. et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell. 24 (2), 257\u2013271 (2013).","journal-title":"Cancer Cell."},{"issue":"3","key":"46619_CR18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1053\/j.gastro.2019.05.002","volume":"157","author":"AA Widjaja","year":"2019","unstructured":"Widjaja, A. A. et al. Inhibiting interleukin 11 signaling reduces hepatocyte death and liver fibrosis, inflammation, and steatosis in mouse models of nonalcoholic steatohepatitis. Gastroenterology 157(3), 777-792e14 (2019).","journal-title":"Gastroenterology"},{"issue":"7","key":"46619_CR19","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1136\/gutjnl-2019-319200","volume":"69","author":"C Heichler","year":"2020","unstructured":"Heichler, C. et al. STAT3 activation through IL-6\/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis. Gut 69 (7), 1269\u20131282 (2020).","journal-title":"Gut"},{"issue":"8","key":"46619_CR20","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/j.1440-1681.2011.05659.x","volume":"39","author":"M Ernst","year":"2012","unstructured":"Ernst, M. & Putoczki, T. L. Stat3: Linking inflammation to (gastrointestinal) tumourigenesis. Clin. Exp. Pharmacol. Physiol. 39(8), 711\u2013718 (2012).","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"5","key":"46619_CR21","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/cas.12638","volume":"106","author":"D Pan","year":"2015","unstructured":"Pan, D. et al. High expression of interleukin-11 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma. Cancer Sci. 106 (5), 592\u2013597 (2015).","journal-title":"Cancer Sci."},{"issue":"22","key":"46619_CR22","doi-asserted-by":"publisher","first-page":"5579","DOI":"10.1158\/1078-0432.CCR-13-2492","volume":"20","author":"M Ernst","year":"2014","unstructured":"Ernst, M. & Putoczki, T. L. Molecular pathways: IL11 as a tumor-promoting cytokine\u2014translational implications for cancers. Clin. Cancer Res. 20 (22), 5579\u20135588 (2014).","journal-title":"Clin. Cancer Res."},{"key":"46619_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9060659","author":"P Maroni","year":"2021","unstructured":"Maroni, P. et al. Interleukin 11 (IL-11): Role(s) in breast cancer bone metastases. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines9060659 (2021).","journal-title":"Biomedicines"},{"issue":"1","key":"46619_CR24","doi-asserted-by":"publisher","first-page":"7316","DOI":"10.1038\/s41467-022-35096-6","volume":"13","author":"Q Sui","year":"2022","unstructured":"Sui, Q. et al. Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer. Nat. Commun. 13 (1), 7316 (2022).","journal-title":"Nat. Commun."},{"key":"46619_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073549","author":"B Ng","year":"2022","unstructured":"Ng, B. et al. IL11 activates pancreatic stellate cells and causes pancreatic inflammation, fibrosis and atrophy in a mouse model of pancreatitis. Int J Mol Sci https:\/\/doi.org\/10.3390\/ijms23073549 (2022).","journal-title":"Int J Mol Sci"},{"key":"46619_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12935-015-0260-7","volume":"15","author":"B Liu","year":"2015","unstructured":"Liu, B., Qu, L. & Yan, S. Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell. Int. 15, 106 (2015).","journal-title":"Cancer Cell. Int."},{"issue":"9","key":"46619_CR27","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1158\/1055-9965.EPI-13-0263","volume":"22","author":"AT Kunzmann","year":"2013","unstructured":"Kunzmann, A. T. et al. PTGS2 (Cyclooxygenase-2) expression and survival among colorectal cancer patients: a systematic review. Cancer Epidemiol. Biomarkers Prev. 22 (9), 1490\u20131497 (2013).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"37","key":"46619_CR28","doi-asserted-by":"publisher","first-page":"59652","DOI":"10.18632\/oncotarget.10831","volume":"7","author":"Z Zhong","year":"2016","unstructured":"Zhong, Z. et al. Interleukin-11 promotes epithelial-mesenchymal transition in anaplastic thyroid carcinoma cells through PI3K\/Akt\/GSK3\u03b2 signaling pathway activation. Oncotarget 7 (37), 59652\u201359663 (2016).","journal-title":"Oncotarget"},{"key":"46619_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.theriogenology.2025.02.012","volume":"237","author":"H Wu","year":"2025","unstructured":"Wu, H. et al. IL-11 regulates the biosynthesis of PGE2 through JAK1\/STAT3 signaling pathway in bovine granulosa cells. Theriogenology 237, 85\u201392 (2025).","journal-title":"Theriogenology"},{"issue":"1","key":"46619_CR30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41698-025-00913-w","volume":"9","author":"C Zhang","year":"2025","unstructured":"Zhang, C. et al. IL-11\/IL-11R signal inhibition by 9MW3811 remodels immune tumor microenvironment and enhances anti-tumor efficacy of PD-1 blockade. NPJ Precis. Oncol. 9(1), 138 (2025).","journal-title":"NPJ Precis. Oncol."},{"issue":"4","key":"46619_CR31","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1158\/1535-7163.MCT-15-0677","volume":"15","author":"AL Winship","year":"2016","unstructured":"Winship, A. L. et al. Targeting Interleukin-11 Receptor-\u03b1 Impairs Human Endometrial Cancer Cell Proliferation and Invasion In Vitro and Reduces Tumor Growth and Metastasis In Vivo. Mol. Cancer Ther. 15 (4), 720\u2013730 (2016).","journal-title":"Mol. Cancer Ther."},{"issue":"8023","key":"46619_CR32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41586-024-07701-9","volume":"632","author":"AA Widjaja","year":"2024","unstructured":"Widjaja, A. A. et al. Inhibition of IL-11 signalling extends mammalian healthspan and lifespan. Nature 632 (8023), 157\u2013165 (2024).","journal-title":"Nature"},{"issue":"6","key":"46619_CR33","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1158\/1078-0432.CCR-24-2920","volume":"31","author":"AM Tsimberidou","year":"2025","unstructured":"Tsimberidou, A. M. et al. Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors. Clin. Cancer Res. 31 (6), 965\u2013974 (2025).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"46619_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.15537\/smj.2022.43.1.20210574","volume":"43","author":"TM Mostafa","year":"2022","unstructured":"Mostafa, T. M., Alm El-Din, M. A. & Rashdan, A. R. Celecoxib as an adjuvant to chemotherapy for patients with metastatic colorectal cancer: A randomized controlled clinical study. Saudi Med. J. 43 (1), 37\u201344 (2022).","journal-title":"Saudi Med. J."},{"issue":"6","key":"46619_CR35","doi-asserted-by":"publisher","first-page":"e13973","DOI":"10.1111\/eci.13973","volume":"53","author":"L Li","year":"2023","unstructured":"Li, L., Zhang, Y. & Qin, L. Effect of celecoxib plus standard chemotherapy on cancer prognosis: A systematic review and meta-analysis. Eur. J. Clin. Invest. 53 (6), e13973 (2023).","journal-title":"Eur. J. Clin. Invest."},{"key":"46619_CR36","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2024.5636","author":"G Zhang","year":"2024","unstructured":"Zhang, G. et al. Role of STAT3 in cancer cell epithelial\u2011mesenchymal transition (Review). Int. J. Oncol. https:\/\/doi.org\/10.3892\/ijo.2024.5636 (2024).","journal-title":"Int. J. Oncol."},{"key":"46619_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107966","volume":"221","author":"J Yu","year":"2025","unstructured":"Yu, J. et al. Interleukin-11: A central integrative hub driving pathological progression from pulmonary inflammation and fibrosis to cancer.. Pharmacol. Res. 221, 107966 (2025).","journal-title":"Pharmacol. Res."},{"issue":"10214","key":"46619_CR38","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde, D. et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet 394 (10214), 2108\u20132117 (2019).","journal-title":"Lancet"},{"issue":"3","key":"46619_CR39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1182\/blood-2017-10-812701","volume":"132","author":"TJ Phillips","year":"2018","unstructured":"Phillips, T. J. et al. Phase 1 study of the PI3K\u03b4 inhibitor INCB040093\u2009\u00b1\u2009JAK1 inhibitor itacitinib in relapsed\/refractory B-cell lymphoma. Blood 132 (3), 293\u2013306 (2018).","journal-title":"Blood"},{"issue":"1","key":"46619_CR40","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1038\/s41467-023-42714-4","volume":"14","author":"Q Tang","year":"2023","unstructured":"Tang, Q. et al. Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin. Nat. Commun. 14 (1), 7099 (2023).","journal-title":"Nat. Commun."},{"issue":"1","key":"46619_CR41","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(23)00589-2","volume":"25","author":"Y Song","year":"2024","unstructured":"Song, Y. et al. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study. Lancet Oncol. 25 (1), 117\u2013125 (2024).","journal-title":"Lancet Oncol."},{"issue":"3","key":"46619_CR42","doi-asserted-by":"publisher","first-page":"e0151939","DOI":"10.1371\/journal.pone.0151939","volume":"11","author":"YY Zhou","year":"2016","unstructured":"Zhou, Y. Y. et al. Clinical profile of cyclooxygenase-2 inhibitors in treating non-small cell lung cancer: A meta-analysis of nine randomized clinical trials. PLoS One 11(3), e0151939 (2016).","journal-title":"PLoS One"},{"key":"46619_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpt.2025.04.002","author":"MS Millat","year":"2025","unstructured":"Millat, M. S. et al. Inflammatory cytokines and specific factors influencing lung cancer progression.. Cancer Pathogenesis and Therapy https:\/\/doi.org\/10.1016\/j.cpt.2025.04.002 (2025).","journal-title":"Cancer Pathogenesis and Therapy"},{"issue":"1","key":"46619_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2024.11.011","volume":"43","author":"CT Kureshi","year":"2025","unstructured":"Kureshi, C. T. & Dougan, S. K. Cytokines in cancer. Cancer Cell. 43 (1), 15\u201335 (2025).","journal-title":"Cancer Cell."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46619-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46619-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46619-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T23:19:35Z","timestamp":1779837575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46619-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,5]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["46619"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-46619-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,5]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures done involving human participants were done in compliance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The ethical sanction was attained from Institutional Ethical Committee. The study protocol was approved by the Ethics Committee of SK Institute of Medical Sciences (IEC\/SKIMS protocol # RP 16\/2020).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Approvals of the patients who participated in this study were obtained through a native written information consent form.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"16368"}}